Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Clearside Biomedical's Revenue for the
three
months ended in Sep. 2025 was €0.17 Mil. Clearside Biomedical's average Accounts Receivable for the
three
months ended in Sep. 2025 was €0.47 Mil.
Hence, Clearside Biomedical's Receivables Turnover for the
three
months ended in Sep. 2025 was 0.37.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Clearside Biomedical Receivables Turnover Related Terms
Clearside Biomedical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CLM0 vs RMTG, ABPO, SCNI: Receivables Turnover Comparison
For the Biotechnology subindustry, Clearside Biomedical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (STU:CLM0) has a Receivables Turnover of 0.37 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #511 out of 840 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Clearside Biomedical's Receivables Turnover too high?
Clearside Biomedical's current Receivables Turnover is 0.37. The Biotechnology industry median Receivables Turnover is 5.28. Clearside Biomedical's value of 0.37 is 93% below this industry median. Based on the distribution chart, Clearside Biomedical ranks #511 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Clearside Biomedical has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Receivables Turnover compare to RMTG and ABPO?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #511 out of 840 companies for Receivables Turnover. This places Clearside Biomedical in the lower half of its industry. The industry median Receivables Turnover is 5.28. Clearside Biomedical's value of 0.37 is 93% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearside Biomedical's current Receivables Turnover of 0.37 is 93% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clearside Biomedical and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current Receivables Turnover is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Clearside Biomedical (STU:CLM0) has a current Receivables Turnover of 0.37. The stock's GF Value™ is €110.06, compared to a current price of €4.35 — trading 96% below its estimated fair value. The current Receivables Turnover is 0.37 and 93% below the Biotechnology industry median of 5.28. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Clearside Biomedical (STU:CLM0), the current Receivables Turnover is 0.37 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.
Key valuation signals for STU:CLM0:
Receivables Turnover: 0.37
GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
Industry Position: 93% below the Biotechnology median (#511 of 840)
No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for STU:CLM0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLM0 has been successfully added to your 
